Evidence map›Paper›PMID 30005673›Full record

ArticleWorld journal of surgical oncology2018

Multimodal treatment of pediatric patients with Askin's tumors: our experience.

Silvia Triarico, Giorgio Attinà, Palma Maurizi, Stefano Mastrangelo, Lorenzo Nanni, Vito Briganti, Elisa Meacci, Stefano Margaritora, Mario Balducci, Antonio Ruggiero

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in World journal of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Silvia TriaricoPaediatric Oncology Unit, A. Gemelli University Hospital, Catholic University of Sacred Hearth, Largo A. Gemelli, 8, 00168, Rome, Italy. silviatriarico@libero.it.
Giorgio AttinàPaediatric Oncology Unit, A. Gemelli University Hospital, Catholic University of Sacred Hearth, Largo A. Gemelli, 8, 00168, Rome, Italy.
Palma MauriziPaediatric Oncology Unit, A. Gemelli University Hospital, Catholic University of Sacred Hearth, Largo A. Gemelli, 8, 00168, Rome, Italy.
Stefano MastrangeloPaediatric Oncology Unit, A. Gemelli University Hospital, Catholic University of Sacred Hearth, Largo A. Gemelli, 8, 00168, Rome, Italy.
Lorenzo NanniPediatric Surgery Unit Gemelli University Hospital, Catholic University of Sacred Heart, Rome, Italy.
Vito BrigantiPediatric Surgery Unit, San Camillo Forlanini Hospital, Rome, Italy.
Elisa MeacciThoracic Surgery Unit, Gemelli University Hospital, Catholic University of Sacred Heart, Rome, Italy.
Stefano MargaritoraThoracic Surgery Unit, Gemelli University Hospital, Catholic University of Sacred Heart, Rome, Italy.
Mario BalducciRadiotherapy Unit, Gemelli University Hospital, Catholic University of Sacred Heart, Rome, Italy.
Antonio RuggieroPaediatric Oncology Unit, A. Gemelli University Hospital, Catholic University of Sacred Hearth, Largo A. Gemelli, 8, 00168, Rome, Italy.
Università Cattolica del Sacro Cuore · ITCarlo Forlanini Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe report our experience and outcomes about the management of Askin's tumors [AT], which are rare primitive neuroectodermal tumors (PNETs) that develop within the soft tissue of the thoracopulmonary region, typically in children and adolescents.

methodsWe retrospectively analyzed the charts of 9 patients affected by AT (aged 6-15 years), treated at the Paediatric Oncology Unit of Gemelli University Hospital in Rome between January 2001 and December 2016.

resultsAll nine patients underwent to biopsy followed by neoadjuvant chemotherapy. At the end of the neoadjuvant chemotherapy, they underwent to surgical removal of the residual tumor. Five patients with positive tumor margins and/or necrosis< 90% received local radiotherapy. Two patients with metastasis received an intensified treatment, with the addition of high dose adjuvant chemotherapy followed by peripheral blood stem cells rescue. No statistically significant correlation was found between outcome and gender; the presence of any metastasis and the radiotherapy. The overall survival was 65.14 months (95% confidence interval [95%CI], 45.81-84.48), and the 5 years survival was 60%, at a median follow-up of 53.1 months.

conclusionOur study confirms that a multimodal treatment with surgery, chemotherapy, and radiotherapy may increase the survival in AT pediatric patients.

Indexed as

AdolescentAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsChildCombined Modality TherapyFemaleHumansMaleNeoadjuvant TherapyNeuroectodermal Tumors, Primitive, PeripheralPeripheral Blood Stem Cell TransplantationPrognosisRadiotherapy, AdjuvantRetrospective StudiesSoft Tissue NeoplasmsSurvival AnalysisAskin’s tumorsPolychemotherapyRadiotherapySurgeryThoracopulmonary region

Identifiers

PMID30005673
PMCPMC6044084
OpenAlexW2883553689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.